All Professionals
Overview
Chris Guerin is an associate in the Securities and Capital Markets practice of Paul Hastings and is based in the firm's New York office. His practice includes representation of clients across the life sciences and technology industries, which include global investment banks as well as public and private companies. Chris advises clients in a variety of capital markets transactions including IPOs, follow-on offerings, and private placements of equity and debt securities, as well as venture financings, mergers and acquisitions, securities law compliance and corporate governance.
Education
- Fordham University School of Law, J.D. (cum laude), 2018
- College of the Holy Cross, B.A., 2012
Representations
- Aktis Oncology, Inc. in its $365 million initial public offering.
- J.P. Morgan Securities and other underwriters in the $82 million initial public offering by CAMP4 Therapeutics Corporation.
- J.P. Morgan Securities and other underwriters in the initial public offering and subsequent PIPE financing by Lexeo Therapeutics, Inc., aggregating over $200 million.
- Leerink Partners and the other underwriters in the $135 million public offering and concurrent private placement by Lexeo Therapeutics, Inc.
- Jefferies, J.P. Morgan Securities and other underwriters in the $130 million follow-on offering and concurrent registered direct offering by ProKidney Corp.
- TD Cowen and the other underwriters in the $125 million follow-on offering by Prime Medicine, Inc.
- Orchestra BioMed in connection with several financing transactions, including its public offering, concurrent private placement transactions and royalty financing transactions, aggregating over $110 million.
- TD Cowen and the other placement agents in Ovid Therapeutics Inc.’s PIPE financing.
- TD Cowen and Evercore ISI in the $80 million private placement by vTv Therapeutics Inc.
- TD Cowen and WedBush PacGrow in the $100 million follow-on offering by Monte Rosa Therapeutics, Inc.
- TD Cowen and other underwriters in follow-on offerings by Humacyte, Inc. aggregating over $95 million.
- Jefferies in the $90 million follow-on offering by Esperion Therapeutics, Inc.
- Leerink Partners in the $80 million follow-on offering by PepGen Inc.
- Piper Sandler and the other placement agents in PIPE financings by Skye Biosciences, Inc., aggregating over $90 million.
- Goldman Sachs & Co. LLC and the other underwriters in follow-on offerings by Syndax Pharmaceuticals, Inc. aggregating over $355 million in proceeds.
- BofA Securities and Goldman Sachs & Co. LLC in the $350 million private placement by Arvinas, Inc.
- Jefferies and Leerink Partners in the $50 million follow-on offering by AC Immune SA.
- Oppenheimer & Co. in the $40 million registered direct offering by Vaxart, Inc.
- Oppenheimer & Co. and Citizens JMP in the $35 million registered direct offering by INOVIO Pharmaceuticals.
- Goldman Sachs & Co. LLC and the other underwriters in the $550 million junior subordinated notes offering by Dentsply Sirona Inc.
- Morgan Stanley, J.P. Morgan Securities, Rabo Securities and other underwriters in the $1.1 billion senior notes offering by AGCO Corporation.
- Morgan Stanley, Goldman Sachs, HSBC, Wells Fargo Securities and other underwriters in the $1.25 billion senior notes offering by Helmerich & Payne.
- Wells Fargo, BofA Securities, J.P. Morgan Securities and other underwriters in the $600 million green bond offering by American Homes 4 Rent.
- Varonis Systems, Inc. in its $400 million convertible senior notes offering.
- Disc Medicine, Inc. in its reverse merger and follow on offerings aggregating over $290 million in proceeds.
- HOOKIPA Pharma Inc. in its follow-on offerings aggregating over $120 million in proceeds.
- Goldman Sachs & Co. LLC in the follow-on offering by Taysha Gene Therapies.
- Goldman Sachs & Co. LLC and other underwriters in the $102 million follow-on offering by Valneva SE.
- J.P. Morgan Securities and other underwriters in the $75 million follow-on offering by Precigen, Inc.
News
- Paul Hastings Advised Morgan Stanley, J.P. Morgan, Rabo Securities and the Other Underwriters in AGCO Corporation’s Inaugural $1.1 Billion Senior Notes Offering - March 26th, 2024
- Paul Hastings advised Piper Sandler and Co. and Oppenheimer & Co. in connection with Skye Bioscence, Inc.’s PIPE - March 12th, 2024
- Paul Hastings advised J.P. Morgan and Leerink Partners in connection with Lexeo Therapuetics’ PIPE - March 11th, 2024
- Paul Hastings Advised Underwriters on Humacyte’s $40 Million Public Offering - March 1st, 2024